Cancer antigen 125: Biochemical properties and diagnostic significance

Jugoslovenska Medicinska Biokemija

Volumn 20, Issue 4, 2001, Pages 201-206

  Janković, Miroslava ^a  

^a INEP ^*  (Serbia)

Author keywords

Benign tumor; CA 125; Differential diagnosis; Glycoprotein; Serous ovarian cancer

Indexed keywords

EID: 0035700218     PISSN: 03543447     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (58)

1. Recent developments in glycoconjugates
2. Mucins as tumor markers
3. Development of immunoradiometric assay for quantitative determination of total IgE
4. Purification of human alfa fetoprotein
5. Glycoproteins: Structure and function
6. Animal soluble beta galactoside binding lectins-galectins. A review
7. Examination of the galectin-3 interaction with immunoglobulin E from sera of allergy patients
8. The effect of Trichinella spiralis infection on the activity of mannose-binding protein in rat liver
9. Pathways of O-glycan biosynthesis in cancer cells
10. Aberrant glycosylation in tumors and tumor-associated carbohydrate antigens
11. Glycoprotein glycosylation and cancer progression
12. Cancer of the urinary and reproductive tracts
13. Complementary cDNA cloning for galactosyltransferase associated with tumor and determination of antigenic epitopes recognized by specific monoclonal antibodies
14. Glycosylation of alpha-1-proteinase inhibitor and haptoglobin in ovarian cancer: Evidence for two different mechanisms
15. Serum sialyl Tn as an independent predictor of poor prognosis in patients with epithelial ovarian cancer
16. CA 125
17. Reactivity of monoclonal antibody with human ovarian carcinoma
18. A radioimmunoassay using monoclonal antibody to monitor the course of epihelial ovarian cancer
19. Isolation of the murine Nbr1 gene adjacent to the murine Brca1 gene
20. Synthesis and secretion of the ovarian cancer antigen CA 125 by the human cancer cell line NIH: OVCAR-3
21. Isolation and characterization of ovarian cancer antigen CA 125 using a new monoclonal antibody (VK-8): Identification as a mucintype molecule
22. More than 15 years of CA 125: What is known about the antigen, its structure and its function
23. Heterogeneity of CA 125 antigens released from human endometrial heterotopic epithelium and ovarian cancer
24. Molecular nature and possible presence of a membranous glycan-phosphatidylinositol anchor of CA 125 antigen
25. Immunoblotting characterization of CA 125 in biological fluids: Difference between pregnancy and cancer CA 125 origin
26. Epidermal growth factor enhances secretion of the ovarian tumor-asociated antigen CA 125 from the human amnion WISH cell line
27. Characterization of the CA 125 antigen associated with human epithelial ovarian carcinoms
28. Characterization of CA 125 synthesized by the human epithelial amnion W1SH cell line
29. An antibody-lectin sandwich assay for the determination of CA 125 antigen in ovarian cancer patients
30. Distribution of CA 125 in embryonic tissues and adult derivatives of the fetal periderm
31. Tissue distribution and characteristics of the CA 125 antigen
32. The tumor marker CA 125 is a common constituent of normal cervical mucus
33. CA 125 antigen in human amniotic fluid and fetal membranes
34. CA 125 and CA 19-9: Two cancer-associated sialylsaccharide antigens on a mucus glycoprotein from human milk
35. Detection of ovarian cancer marker CA 125 in human seminal plasma
36. Tumor markers in the human ovary and neoplasms. A comparative immunohistochemical study
37. Effect of menstruation on serum CA 125 levels
38. A new serological index for low-grade non-Hodgkins lymphoma based on initial CA 125 and LDH serum levels
39. Specificity and affinity of 26 monoclonal antibodies against the CA 125 antigen: First report from the OSOBM TD-1 Workshop
40. Immunohistochemical characterization of 22 monoclonal antibodies against the CA 125 antigen: 2nd Report from the ISOBM TD-1 Workshop
41. Comparison of the first-generation and three second-generation methods for determination of CA 125
42. Comparison between Centcor CA 125 and CA 125 II assays
43. Study of the nature of interfering substances responsible for non-specific reactive phenomena occurred occasionally in EIA determination of CA 125
44. Quantitation of IgG and IgM human anti-mouse antibodies (HAMA) interference in CA 125 measurements using affinity chromatography
45. The performance of screening tests for ovarian cancer: Results of a systematic review
46. The role of tumor marker CA 125 in treatment of ovarian cancer
47. Ovarian cancer. Age contrasts in incidence, histology, disease stage at diagnosis, and mortality
48. Preoperative value of CA 125 as a reflection of tumor grade in epithelian ovarian cancer
49. Biological variation and analytical imprecision of CA 125 in patients with ovarian cancer
50. CA 125 measured before second-look laparotomy is an independent prognostic factor for survival in patients with epithelial ovarian cancer
51. Serum concentrations of cancer antigen 125, placental alkaline phosphatase, cancer-associated serum antigen and free beta human chorionic gonadotrophin as prognostic markers for epithelian ovarian cancer
52. Serum lipid-associated sialic acid (LSA) in diagnosing and monitoring ovarian cancer
53. The management of ovarian carcinoma is improved by the use of cancer-associated serum antigen and CA 125 assay
54. Use of tetranectin, CA 125 and CASA to predict residual tumor and survival at second- and third-look operations for ovarian cancer
55. Serum mucin antigens CASA and MSA in tumors of the breast, ovary, lung, pancreas, bladder, colon, and prostate. A blind trial with 420 patients
56. Objective interpretation of results for tumor markers